AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/41097 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve TURBT skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc.

There are no comments yet.

Please log in to write the first comment.